CORESTEMCHEMON Inc. (KOSDAQ:166480)

South Korea · Delayed Price · Currency is KRW

1,949.00

+48.00 (2.52%)

At close: Oct 16, 2026

Market Cap	86.46B +112.8%
Revenue (ttm)	18.29B -26.3%
Net Income	-27.81B
EPS	-681.41
Shares Out	44.36M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	179,142
Open	1,950.00
Previous Close	1,901.00
Day's Range	1,890.00 - 2,040.00
52-Week Range	1,014.00 - 6,100.00
Beta	1.62
Analysts	n/a
Price Target	n/a
Est. Earnings	Nov 13, 2026

About CORESTEMCHEMON

CORESTEMCHEMON Inc., a bio-pharmaceutical company, engages in the development and production of stem cell therapies for the treatment of incurable diseases in South Korea. It offers NEURONATA-R inj, an autologous bone marrow mesenchymal stem cell therapy for the treatment of amyotrophic lateral sclerosis (ALS). The company also engages in the development of various therapy products for the treatment of systemic lupus erythematosus (SLE), multiple system atrophy (MSA), and cerebellar ataxia (CA) diseases. The company has a strategic partnership ... [Read more]

Industry Biological Products, Except Diagnostic Substances

Founded 2003

Employees 289

Stock Exchange KOSDAQ

Ticker Symbol 166480

Full Company Profile

Financial Performance

In 2025, CORESTEMCHEMON's revenue was 20.16 billion, a decrease of -29.91% compared to the previous year's 28.76 billion. Losses were -26.83 billion, 2.21% more than in 2024.

Financial Statements